deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT00639639

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ATTAC)

Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia

Sponsor: Gary Archer Ph.D.

Conditions Malignant Neoplasms of Brain
Interventions tetanus toxoid therapeutic autologous dendritic cells therapeutic autologous lymphocytes
Updated 14 times since 2017 Last updated: Mar 9, 2023 Started: Feb 6, 2006 Primary completion: Apr 15, 2017 Completion: Jun 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Malignant Neoplasms of Brain and is currently completed. Gary Archer Ph.D. leads this study, which shows 14 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Sep 2019 · 9 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Feb 2022 · 12 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 9 earlier versions

  1. Feb 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  6. Dec 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gary Archer Ph.D.
  • National Cancer Institute (NCI)
Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations